Healthcare
AVCJ Awards 2020: Operational Value Add: Nexus Day Hospitals
Having formed Australia-based Nexus Day Hospitals by merging two smaller operators, Mercury Capital led a wholesale expansion and professionalization of the business
Qiming raises $441m for its sixth renminbi fund
Qiming Venture Partners has closed its sixth renminbi-denominate vehicle at RMB2.85 billion ($441 million), taking the firm's total assets under management to $5.9 billion.
Chinese medical robot maker raises $93m
Edge Medical, a China-based manufacturer of surgical robots, has raised a RMB600m ($93m) series B round led by Lyfe Capital and Hong Kong-listed Kangji Medical.
Hopu founder backs China healthcare-focused SPAC
Fenglei Fang, founder and chairman of Chinese private equity firm Hopu Investments, is looking to raise $300 million for a special purpose acquisition company (SPAC) that will target healthcare companies with a China focus or expansion prospects in the...
Riverside to buy Australian insurance broker
The Riverside Group has agreed to acquire a controlling stake in Australian disability insurance broker Altius from Sydney-listed AUB Group for A$57 million ($44.3 million) in cash.
China's BangEr Orthopedic raises $46m
Chinese hospital chain operator BangEr Orthopedic has raised a RMB300 million ($46 million) Series D round led by Fortune Capital and Cenova Capital.
Tower Capital hits first close on Southeast Asia fund
Tower Capital, a Singapore-based GP that previously operated on a deal-by-deal basis, has achieved a first close of approximately $250 million on its first Southeast Asia-focused private equity fund.
Sinovation sharpens focus on healthcare-plus-AI
Healthcare, rather than “rocket science,” represents the biggest opportunity for artificial intelligence (AI) applications, according to Kai-Fu Lee, chairman and CEO of China’s Sinovation Ventures.
Deal focus: Monetizing mice
ORI Capital’s 2.8x return on its investment in Kymab was in part based on helping the company make the transition from antibody-based discovery platform to drug development engine
Hillhouse founder bullish on China life sciences
Lei Zhang, founder and CEO of Hillhouse Capital, emphasized the opportunities at the nexus of life sciences and artificial intelligence-enabled supercomputing, while describing his firm as “probably the largest investor in healthcare in China.”
Lake Bleu raises $560m for Asia pre-IPO healthcare fund
Lake Bleu Capital, a Hong Kong-based private equity investor focused on healthcare, has raised $560 million for a pre-IPO fund targeting Asia with an emphasis on Greater China.
Fund focus: Oceanpine opens to external capital
Technology and healthcare-focused Oceanpine Capital sees the large GP commitment to its fund and the network of its founder as key differentiators in a competitive Chinese market
China’s CICC raises $650m for biomedical fund
CICC Capital has reached a second close of RMB4.2 billion ($650 million) on its latest healthcare fund - the first in China to receive fast-track approval for its role in addressing COVID-19.
Hong Kong's ORI hits first close on Fund II, exits Kymab
Hong Kong healthcare-focused VC firm ORI Capital has reached a first close of $112 million on its second fund and exited its largest investment, UK biotech developer Kymab, as part of a $1.1 billion deal.
Cathay closes second innovation fund $789m
Cathay Capital has raised EUR650 million ($789 million) for its second innovation fund, which supports start-ups in China, Europe, and North America.
Sequoia leads $150m Series B for China's Visen Pharma
China’s Visen Pharmaceuticals, a drug developer targeting glandular conditions such as dwarfism and growth deficiency has raised a $150 million Series B round led by Sequoia Capital China.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
GIC leads $203m investment in Vietnam hospital
A GIC-led consortium has agreed to invest VND4.7 trillion ($203 million) in Vinmec, a leading Vietnamese hospital developer and operator.
China's Oceanpine raises $400m for tech, healthcare deals
Chinese technology and healthcare investor Oceanpine Capital has completed its first external fundraise with $400 million in commitments.
Trustbridge leads $500m round for China's Dxy.cn
Trustbridge Partners has led a $500 million round for Dingxiangyuan – also known as dxy.cn – a Chinese digital medical platform that primarily serves as a forum for healthcare industry professionals.
The crystal ball: Predictions for 2021
Industry professionals process the upheavals of 2020 to inform outlooks for a range of markets and investment themes. Realist bullishness abounds
J-Star acquires Japan drug wholesaler Genex
Japanese private equity firm J-Star has taken a controlling stake in local pharmaceuticals wholesaler Genex for an undisclosed sum.
China healthtech player gets $100m Series C extension
Weimai, a Chinese healthcare-focused big data platform that primarily serves hospitals and clinics in lower-tier cities, has raised $100 million in an extended Series C round led by Baidu Capital.
PE-backed Harbour BioMed raises $221m in Hong Kong IPO
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.